Hillstream BioPharma (NASDAQ:HILS) Trading Down 3.4%

Hillstream BioPharma, Inc. (NASDAQ:HILSGet Free Report) traded down 3.4% during trading on Friday . The company traded as low as $0.23 and last traded at $0.24. 215,668 shares were traded during mid-day trading, a decline of 85% from the average session volume of 1,447,404 shares. The stock had previously closed at $0.24.

Analyst Upgrades and Downgrades

Separately, Dawson James cut shares of Hillstream BioPharma from a “buy” rating to a “neutral” rating in a research report on Monday, July 17th.

View Our Latest Stock Analysis on HILS

Hillstream BioPharma Price Performance

The stock’s fifty day moving average is $0.31 and its 200-day moving average is $0.56. The stock has a market cap of $4.16 million, a PE ratio of -0.33 and a beta of 3.08.

Hillstream BioPharma (NASDAQ:HILSGet Free Report) last announced its quarterly earnings data on Friday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). On average, sell-side analysts expect that Hillstream BioPharma, Inc. will post -0.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new stake in shares of Hillstream BioPharma during the third quarter worth about $36,000. Geode Capital Management LLC acquired a new stake in shares of Hillstream BioPharma during the first quarter worth about $30,000. Finally, Jane Street Group LLC acquired a new stake in Hillstream BioPharma in the first quarter valued at approximately $38,000. Hedge funds and other institutional investors own 13.36% of the company’s stock.

About Hillstream BioPharma

(Get Free Report)

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors.

Recommended Stories

Receive News & Ratings for Hillstream BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hillstream BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.